← All trials
NCT04569409
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 14, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Sep 29, 2020
- Last posted
- Sep 29, 2020
- Enrollment
- 104
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Anterogen Co., Ltd.Lead sponsor
- Korea UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- University of UlsanOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.